Cochrane · systematic review · CD003352
Dopamine agonists for the treatment of cocaine dependence
Minozzi, S, Amato, L, Pani, PP, et al. · Cochrane Database of Systematic Reviews · 2015 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
12
current version
GRADE rated
12
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 6 · 50%Moderate 6 · 50%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlyAny dopamine agonist versus placebo for the treatment of cocaine dependence
Population: patients with the treatment of cocaine dependence
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Dropouts Any dopamine agonist vs placebo | RR 1.04 [0.94, 1.14] | 20 studies · 1656 participants | Moderate Downgraded: risk of bias |
Adverse events as N of participants with at least one adverse event Any dopamine agonist vs placebo | RR 1.27 [0.66, 2.44] | 7 studies · 252 participants | Moderate Downgraded: risk of bias |
Abstinence (objective) Participants abstinent at the end of treatment (N) Any dopamine agonist vs placebo | RR 1.12 [0.85, 1.47] | 11 studies · 731 participants | Low Downgraded: risk of bias, inconsistency |
Abstinence at Any dopamine agonist vs placebo | RR 1.1 [0.61, 1.98] | 4 studies · 136 participants | Low Downgraded: risk of bias, inconsistency |
Severity of dependence (difference before and after) Any dopamine agonist vs placebo | no estimate extracted | 4 studies · 202 participants | Low Downgraded: risk of bias, inconsistency |
Amantadine versus placebo for the treatment of cocaine dependence
Population: patients with the treatment of cocaine dependence
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Dropouts Amantadine vs placebo | RR 0.98 [0.77, 1.26] | 9 studies · 484 participants | Moderate Downgraded: risk of bias |
Adverse events as N of participants with at least one adverse event Amantadine vs placebo | RR 1.19 [0.69, 2.06] | 4 studies · 128 participants | Moderate Downgraded: risk of bias |
Abstinence (objective) N of subjects abstinent at the end of the study Amantadine vs placebo | RR 1.13 [0.59, 2.13] | 5 studies · 275 participants | Low Downgraded: risk of bias, inconsistency |
Abstinence at Amantadine vs placebo | RR 1.49 [1.03, 2.15] | 3 studies · 76 participants | Moderate Downgraded: risk of bias |
Amantidine versus antidepressants for the treatment of cocaine dependence
Population: patients with the treatment of cocaine dependence
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Dropouts Amantidine vs antidepressants | RR 0.86 [0.48, 1.53] | 4 studies · 153 participants | Moderate Downgraded: risk of bias |
Adverse events as N of participants with at least one adverse event Amantidine vs antidepressants | RR 0.56 [0.18, 1.77] | 2 studies · 44 participants | Low Downgraded: risk of bias |
Abstinence (objective) N of subjects abstinent at the end of the study Amantidine vs antidepressants | RR 0.25 [0.12, 0.53] | 2 studies · 68 participants | Low Downgraded: risk of bias |
Any dopamine agonist versus placebo for the treatment of cocaine dependence
Population: patients with the treatment of cocaine dependence
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Dropouts objective Any dopamine agonist vs placebo | RR 1.05 [0.95, 1.15] | 19 studies · 1643 participants | Moderate Downgraded: risk of bias |
Adverse events as N of participants with at least one adverse event subjective and objective Any dopamine agonist vs placebo | RR 1.29 [0.88, 1.91] | 6 studies · 210 participants | Moderate Downgraded: risk of bias |
Abstinence (objective) objective Any dopamine agonist vs placebo | RR 1.09 [0.93, 1.28] | 11 studies · 761 participants | Low Downgraded: risk of bias |
Abstinents at Any dopamine agonist vs placebo | OR 0.81 [0.41, 1.57] | 4 studies · 166 participants | Low Downgraded: risk of bias |
Severity of dependence (difference before and after) ASI Any dopamine agonist vs placebo | no estimate extracted | 4 studies · 232 participants | Moderate Downgraded: risk of bias |
Depression (difference before and after ) Beck Depression Inventory Any dopamine agonist vs placebo | no estimate extracted | 5 studies · 322 participants | Moderate Downgraded: risk of bias |
Amantadine versus placebo for the treatment of cocaine dependence
Population: patients with the treatment of cocaine dependence
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Dropouts objective Amantadine vs placebo | RR 0.98 [0.77, 1.26] | 9 studies · 484 participants | Moderate Downgraded: risk of bias |
Adverse events as N of participants with at least one adverse event objective Amantadine vs placebo | RR 1.09 [0.69, 1.74] | 4 studies · 128 participants | High |
Abstinence (objective) objective Amantadine vs placebo | RR 1.08 [0.77, 1.51] | 5 studies · 275 participants | Moderate Downgraded: risk of bias |
Abstinence at Amantadine vs placebo | RR 1.43 [0.99, 2.08] | 3 studies · 76 participants | Moderate Downgraded: risk of bias |
Amantidine versus antidepressants for the treatment of cocaine dependence
Population: patients with the treatment of cocaine dependence
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Dropouts objective Amantidine vs antidepressants | RR 0.9 [0.57, 1.44] | 4 studies · 153 participants | Moderate Downgraded: risk of bias |
Adverse events as N of participants with at least one adverse event objective Amantidine vs antidepressants | RR 0.54 [0.17, 1.7] | 2 studies · 44 participants | High |
Abstinence (objective) objective Amantidine vs antidepressants | RR 0.25 [0.12, 0.53] | 2 studies · 68 participants | High |